The American Association of Psychiatric Pharmacists (AAPP) represents about 3,000 health care professionals that work as a treatment team of health care professionals, psychiatric pharmacists make a difference in patient recovery and quality of life
Address: 8055 O Street Suite S113 Lincoln, NE 68510
Country: United States of America
The American Association of Psychiatric Pharmacists (AAPP) focuses on serving psychiatric pharmacists and aspiring psychiatric pharmacists and advancing their reach and practice. As the philanthropic arm of AAPP, our mission is to advance the psychiatric pharmacy profession by supporting research, scholarship, and practitioner development.
Address: 8055 O Street Suite S113 Lincoln, NE 68510
Country: United States of America
The American College of Neuropsychopharmacology (ACNP) is a professional, international organization of leading brain scientists. ACNP is a non-profit, professional society dedicated to advancing the scientific understanding of and facilitating communication about disorders of the brain and behavior in order to advance their prevention and treatment. The membership of the College is drawn from scientists in diverse subfields of neuroscience, including behavioral pharmacology, clinical psychopharmacology, epidemiology, genetics, molecular biology, neurochemistry, neuroendocrinology, neuroimaging, neuroimmunology, neurophysiology, neurology, psychiatry, and psychology. The ACNP encourages participation in College activities by members of organizations whose mission and purpose is primarily to:
The principal functions of the College are research, education, to offer investigators the opportunity for cross-disciplinary communication and to promote the application of various neuroscientific disciplines to the study of all forms of mental illness and their treatment. Their educational goals are to encourage young scientists to enter research careers in neuropsychopharmacology and to develop and provide accurate information about psychiatric disorders and treatment. The makeup of the ACNP allows us to offer expertise in the science of psychiatric disorders from the standpoint of diagnostics and therapeutics.
The Roland R. Griffiths, Ph.D., Professorship Fund aims for the endowment is to ensure that rigorous research on psychedelics, spirituality, and well-being. This research will extend Roland R. Griffiths’ pioneering studies on psychedelics into programmatic lines of research.
Address: 5034-A Thoroughbred Lane, Brentwood, TN 37027
Country: United States of America
Email: acnp@acnp.org
The Asian College of Neuropsychopharmacology (AsCNP) is an organisation that aims to encourage research an collaboration to facilitate the communication of ideas in convergent disciplines of neuropsychopharmacology in Asia, develop new pharmacotherapies for the treatment for psychiatric and neurological disorders, provide education and training opportunities, and empower patients and their families with professional knowledge. AsCNP holds congress every 2 years. Their members include:
Address: c/o A & E Planning Co., Ltd. Hitotsubashi Bekkan 4F, 2-4-4 Hitotsubashi, Chiyoda-ku, Tokyo
Country: Japan
Email: secretariatascnp.org
The Association of British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. Their members supply cutting edge treatments that improve and save the lives of millions of people, working in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines.
ABPI aim to research, develop and use the medicines and vaccines of the future by focusing on improving access to new medicines and vaccines so everyone in the UK can get the latest treatments., building a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines, enhancing reputation by demonstrating the high ethical standards we set ourselves and that society expects from us, working in partnership with Government, the NHS and the life science community, providing UK leadership to drive global medicines policy, improving how health data can transform medicine development and improve patient care and representing their members using their insight and experience to tell the story of how they change the lives of millions of people every day.
Address: 2nd Floor Goldings House Hay’s Galleria 2 Hay’s Lane London SE1 2HB
Country: United Kingdom
Email: pressoffice@abpi.org.uk
Rachel Waddington is an experienced independent international trainer and consultant specialising in innovative ways of supporting people who struggle with extreme states (including ‘psychosis’, ‘dissociation’ and post traumatic reactions). As well as having over 14 years of experience within the adult mental health field, I also have particular expertise in working with children, young people and people in prison who hear voices/see visions. Drawing on and sharing her own experiences, Rachel’s workshop on taboo and violent voices provides an insightful and illuminating introduction to topics that are usually considered off-limits. Her honest approach and the stimulating discussion she generated certainly expanded our group’s understanding and empathy for those dealing with such voices. In conjunction with Open Dialogue UK and an NHS trust, I am also undertaking Open Dialogue work as part of my 3 year training as an Open Dialogue Practitioner.
Email: rachel@behindthelabel.co.uk.
BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders.
Address: 780 Brannan Street San Francisco, CA 94103
Country: United States of America
The Choice and Medication website offers patient information about mental health conditions and the treatments available to help make informed decisions about choosing the right medicine. Choice and Medication is commercially available on subscription to healthcare organisations for licensed access by staff and service users. Choice and Medication is produced and maintained by national experts to provide answers to the most commonly asked questions about mental health medicines and conditions.
Address: 2 Geps Place Ashington Northumberland NE638HH
Country: United Kingdom
Email: admin@choiceandmedication.org.uk
The College of Mental Health Pharmacy aims to advance education and research in the practice of mental health pharmacy. College members enjoy access to education and networking opportunities such as egroups, bulletins and the annual conference. The College of Mental Health Pharmacy (CMHP) is a charity which aims to benefit individual care through advancing education and research in the practice of mental health pharmacy. The College delivers this by a combination of:
Address: 23 Southway, Burgess Hill, West Sussex RH15 9SY
Country: United Kingdom
Email: cmhpcomms@cmhp.org.uk
The Collegium Internationale Neuropsychopharmacologicum (CINP) encourages and provides educational activities in the field of neuropsychopharmacology. It advances experimental and clinical aspects of neuropsychopharmacological sciences, facilitates relations between disciplines and considers medico-social problems of psychopharmacology.
Address: c/o Auditreu Gonzagagasse 17 1010 Vienna Vienna
Country: Austria
The Council for Evidence-based Psychiatry (CEP) exists to communicate evidence of the potentially harmful effects of psychiatric drugs to the people and institutions in the UK that can make a difference. The scientific record clearly shows that psychiatric medications, portrayed as safe and effective by areas of the medical profession, often lead to worse outcomes for many patients, particularly when taken long term. Their members include psychiatrists, academics, withdrawal support charities and others who are concerned about the prevalence of the ‘medical model’ and the increasing numbers of prescriptions for psychiatric drugs being given to both adults and children.
Country: United Kingdom
Datapharm is a medical information company that provides technology-enabled solutions to the global life sciences and wider healthcare sectors. Its leading platforms improve the accessibility and usability of medical information.
Address: https://www.datapharm.com/careers/
Country: United Kingdom
Email: +44 1372 371444
Drug Information Association (DIA) is a global, member-driven organization mobilizing life sciences and healthcare professionals. DIA's members come together to collaborate and problem-solve, discussing global and local challenges facing the life sciences field in an increasingly more complex and interconnected world. DIA's collaborations aim to result in better policies, regulations, science, research and development, and ultimately better patient outcomes worldwide. DIA fosters innovation to improve health and well-being worldwide by:
Address: 21 Dupont Cir NW, Washington D.C., DC, Washington, District of Columbia
Country: United States of America
Email: dia@diahome.org
Drugwatch is a consumer advocacy organization that works side by side with award-winning certified medical and legal experts to educate the public on dangerous drugs and medical devices and to empower consumers to assert their legal rights. Their experts help ensure that the medical and legal information is honest, objective and helpful. Drugwatch.com is the go-to resource for information about the prescription drugs, medical devices, conditions and procedures, and available legal options. The team of experienced writers sifts through complex medical journals, court records and government documents to provide important information, in a range of languages.
Country: United States of America
Email: information@drugwatch.com
The ECT quality register contains data on ECT treatment in Sweden. The task of the registry is to collect and analyze patient data. The register provides opportunities to follow up clinical guidelines for treatment. National statistics can help ensure that access to treatment is equal and that treatment is given to patients who benefit from the form of treatment. A registry can also facilitate research into the short-term and long-term effects of treatment. The goal is improved efficacy and minimized side effects.
Address: Quality register ECT , S-building, floor 1. Box 1613, 701 16 Örebro
Country: Sweden
Email: tove.elvin@regionorebrolan.se
The Electronic Medicines Compendium provides up to date, approved and regulated prescribing and patient information for licensed medicines. eMC provides access to the most comprehensive and up to date medicine database in the UK
Country: United Kingdom
The European Behavioural Pharmacology Society (EBPS) is an international society at the crossroads of pharmacology, experimental psychology, psychiatry, and neuroscience. EBPS holds workshops and meetings for its members every 2 years.
The European College of Neuropsychopharmacology is a scientific association dedicated to ensuring that advances in the understanding of brain function translate into better treatments and enhanced public health. ECNP is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health. ECNP aims to:
To achieve its aims, ECNP organises a wide range of activities, programmes and events across Europe. These include:
ECNP Networks bring together researchers with different expertise across Europe to foster successful collaboration and sharing ofideas, discoveries and practices in translational neuroscience. The overarching aim of ECNP Networks is to facilitate the collection of essential biological, clinical and therapeutic data in a standardised way to guarantee their robustness, reproducibility and translatability. The Networks form a matrix of disease-oriented and transnosological groups. In response to the ongoing developments in brain research and the changing nature of the European and international research funding landscape, the ECNP Networks Board instituted the ECNP Thematic Working Groups (TWGs) as a way to further stimulate the Networks activities and facilitate their missions.
Address: Daltonlaan 400 3584 BK Utrech
Country: Netherlands
Email: secretariat@ecnp.eu
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 41 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Address: Leopold Plaza Building, Rue du Trone 108, B-1050 Brussels
Country: Belgium
Email: https://www.efpia.eu/
The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and pharmacy premises in England, Scotland and Wales. Their role is to make sure people receive safe and effective pharmacy care and have trust in pharmacy. They promote professionalism within pharmacy, help make sure pharmacists and pharmacy technicians have the appropriate knowledge, attitudes and behaviours, assure the quality of pharmacy and support the improvement of pharmacy. The General Pharmaceutical Council:
Inspect registered pharmacies to help pharmacies improve their systems and services, the quality of care and the outcomes for patients and the public using their services.
Country: United Kingdom
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations.
#TeamVaccines spotlights the positive impact of vaccines on the world, explains the benefits of vaccines at every age and stage of life, and champions their future potential to save even more lives.
Address
Chemin des Mines 9 1202 Geneva
Country
Switzerland
Contact Person / Email
info@ifpma.org
50 Years of Progress is an initiative that engages with the personal stories of individuals whose lives have been transformed over 50 years of building a better world through health innovations, overcoming challenges, making scientific advances, and partnering for progress.
Country
Switzerland
Contact Person / Email
info@ifpma.org
Global Health Progress explores how the innovative pharmaceutical industry is collaborating with global health actors to achieve the Sustainable Development Goals (SDGs).
Contact Person / Email
info@globalhealthprogress.org
The COVID-19 Innovation Timeline is an initiative that discovers the innovative pharmaceutical industry’s response to the COVID-19 pandemic to inform how we can better prepare for the next public health crisis.
Address
Chemin des Mines 9, 1202 Geneva
Country
Switzerland
Contact Person / Email
https://www.facebook.com/IFPMA
#TogetherAgainstFlu campaign continuously raises awareness of the importance of flu vaccinations for healthcare workers, older adults, and patients living with chronic conditions.
Address
Chemin des Mines 9, 1202 Geneva
Country
Switzerland
Contact Person / Email
info@ifpma.org
Address: Chemin des Mines 9, 1202 Geneva
Country: Switzerland
Postal Address: P.O. BOX 195 1211 Geneva 20
Email: info@ifpma.org
Japanese Pharmaceutical Manufacturers Association (JPMA) is a voluntary association comprising 71 research-oriented pharmaceutical companies. They are engaged with various initiatives and activities to deepen understanding of pharmaceuticals and international collaboration with concerned parties. In particular they are promoting sound development of the pharmaceutical industry by developing policy, strengthening recommendations, facilitating to internationalization of the industry, and boosting public relations.
Country: Japan
The Japanese Society of Psychotherapy and Pharmacotherapy is an academic society in the clinical practice of psychiatry and psychology. It provides a place to learn about the strengths of psychiatry and psychology and pursues the best psychotherapy for each case beyond the schools of thought. The Society awards the European and Japanese Psychotherapist Qualification to those who have received sufficient psychotherapy education and clinical experience.
Address: 154-0015-2 Sakurashinmachi, Setagaya-ku, Tokyo 25-15
Country: Japan
Email: office@nihon-psychotherapy.jp
Karuna Pharmaceuticals are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
KarXT is Karuna's lead product candidate that selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s. Karuna assessed the potential of over 7,000 possible combinations of muscarinic receptor agonists and antagonists to find an optimized combination that could preferentially stimulate muscarinic receptors in the CNS to improve the symptoms of psychosis, while avoiding stimulation of muscarinic receptors in the peripheral tissues and the associated side effects. As a result of our research, we identified xanomeline and trospium as the most promising pairing for development in the form of KarXT (Karuna-xanomeline-trospium). Trospium is a potent and effective muscarinic receptor antagonist that does not measurably cross the blood-brain barrier, confining its effects to peripheral tissues, and it currently marketed for the treatment of overactive bladder in the U.S. and other territories worldwide. Karuna co-founder and chief operating officer, Andrew Miller, Ph.D., was responsible for identifying the initial hypothesis and driving the execution of the completed Phase I studies supporting the combination of xanomeline and trospium.
Despite xanomeline’s promising therapeutic benefit in treating psychosis and related behavioral symptoms in patients with schizophrenia and AD, its potential has been limited by cholinergic side effects, which are believed to result from the stimulation of muscarinic receptors in peripheral tissues. Karuna believes that the above data, as well as our Phase 1 and 2 clinical trials with KarXT demonstrating robust efficacy and significant reductions in the adverse events associated with xanomeline, support the further development of KarXT in multiple neuropsychiatric disorders, including schizophrenia and dementia-related psychosis.
Current antipsychotic treatments rely on the same primary mechanism of action (MOA) as they did when the first antipsychotic was discovered in the 1950s: inhibiting D2 dopamine receptors. Current antipsychotics are often used by physicians to address a wide range of neuropsychiatric disorders in addition to schizophrenia, including bipolar disorder and psychotic depression, as well as psychosis and agitation in elderly patients with dementia, but are associated with modest efficacy and significant side effects.
Muscarinic receptor agonists emerged in the 1990s as a promising innovative approach for treating psychosis and cognitive impairment. Muscarinic receptors are g-protein linked receptors (GPCRs) that bind the neurotransmitter acetylcholine. There are five distinct muscarinic receptors, M1-M5, found in the brain as well as various peripheral tissues.
The link between muscarinic receptor stimulation in the CNS, particularly stimulation of M1 and M4 receptors, and the reduction of psychotic symptoms and cognitive impairment, has been well studied and is supported by data from preclinical studies and randomized, double-blind, placebo-controlled clinical trials with xanomeline published in peer reviewed journals. However, the successful development of a therapeutic agent targeting muscarinic receptors has been limited by undesirable side effects that are believed to arise primarily as a result of stimulation of muscarinic receptors in peripheral tissues. We believe a therapeutic agent that can preferentially target and stimulate muscarinic receptors in the CNS, but not in peripheral tissues, has the potential to treat psychosis in schizophrenia and AD, including the associated agitation in patients with AD. We also believe the preferential stimulation of M1 and M4 muscarinic receptors in the CNS may address the negative symptoms of schizophrenia, such as apathy, reduced social drive and loss of motivation, as well as cognitive deficits in working memory and attention, all of which currently lack any approved treatments. This approach has the potential to produce a differentiated therapy relative to current D2 dopamine receptor-based antipsychotic drugs and to beneficially impact the lives of millions of patients with schizophrenia and other psychotic and cognitive disorders.
Karuna's pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
Address: 33 Arch Street Suite 3110 Boston, MA 02110
Country: United States of America
Email: info@karunatx.com
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. Their responsibilities are to:
Address: MHRA 10 South Colonnade London E14 4PU
Country: United Kingdom
Email: MHRA 10 South Colonnade London E14 4PU
The MIND Foundation is a a psychedelic research and education organization committed to a healthier, more connected world through evidence-based, safe, and legal applications of the psychedelic experience.
The Augmented Psychotherapy Training (APT) is a two-year program that provides you with the knowledge and skills you need to practice psychedelic-augmented psychotherapy and psychedelic integration therapy in a legal, safe, and evidence-based framework.
Country
Germany
Contact Person / Email
https://mind-foundation.org/apt
Beyond Experience is a course that provides a comprehensive skill set for working with the whole spectrum of psychedelic experiences, both personally and when supporting others. The course’s main goal is to engage in a deep integration process and help you remember and express your psychedelic experiences.
Contact Person / Email
integration@mind-foundation.org
Footsteps is an online integrated journey in which you learn to integrate psychedelic experiences online. Over the course of six weeks, you will reconnect deeply with one of your psychedelic experiences in order to identify and embody the insights you have gained in sustainable ways.
The MIND Integration Facilitator Training is training for those who have participated in BEYOND EXPERIENCE (BE) and FOOTSTEPS and want to bring the integrative approach to the psychedelic experience into the world.
The MIND Philosophy series intends to provide an accessible overview of philosophical issues that arise in relation to psychedelics, psychedelic use, and psychedelic research.
The Molecules Program offers a unique transdisciplinary and evidence-based approach to knowledge about psychoactive substances. Being the first program of its kind, we have developed this platform for academics, health practitioners, and the general public. You will be able to acquire and integrate knowledge and practices from different disciplines and professions.
The EPIsoDE Study is being conducted by the Central Institute of Mental Health (CIMH) in Mannheim, Germany (Principal Investigator: Prof. Dr. med. Gerhard Gründer). A second study center has been established at Charité Universitätsmedizin Berlin. The study is funded by the German Federal Ministry of Education and Research (BMBF). The MIND Foundation is an official study partner providing expertise, personnel, and additional funding.
The acronym “EPIsoDE” (Efficacy and safety of Psilocybin In treatment-reSistant majOr DEpression) summarizes the aim of the study: To investigate whether psilocybin administered under supportive conditions in a controlled, randomized, double-blind design is a safe and effective treatment for depression patients whose symptoms cannot be adequately reduced with antidepressants. Over the course of the study, 144 patients will be treated in Mannheim and Berlin. The rationale and study design are explained in detail in a recent article published in the scientific journal Neuroscience Applied.
uniMIND is a global network of academic journal clubs, open to academics of all levels and disciplines with the focus on mind, brain, and psychedelic research. Local groups operate mostly autonomously through regular meetings in which research literature, academic talks, documentaries, or projects are discussed. Besides, there are monthly central web-sessions with invited authors and the yearly uniMIND Symposium.
Address: Boxhagener Straße 82a 10245 Berlin
Country: Germany
Email: info@mind-foundation.org
The National Pharmacy Association is the representative voice of independent community pharmacies across the UK and a leading provider of services to the entire sector. Their aim is to support independent community pharmacies to succeed professionally and commercially for the benefit of their patients. As a not-for-profit organisation we are committed to reinvesting in service provision.
Address: Mallinson House 38-42 St Peters Street St. Albans Hertfordshire AL1 3NP
Country: United Kingdom
Email: npa@npa.co.uk
NPS MedicineWise is the National Prescribing Service (NPS) that supports quality use of medicines to improve health decisions and health and economic outcomes in Australia.
Biologics and other specialised medicines have made a significant improvement in the management of chronic diseases like inflammatory arthritis, inflammatory bowel disease and plaque psoriasis. ​On this page you will find evidence-based resources to support consumers and health professionals to make safe and wise decisions for using these medicines.
Country
Australia
Choosing Wisely Australia is a national conversation about reducing unnecessary tests, treatments and procedures
Country
Australia
A database created by NPS Medicinewsie wehre you can learn more about many types of medicines that are prescribed or recommended for treatment.
Country
Australia
MedicineInsight is a quality improvement program developed and managed by NPS MedicineWise with funding from the Australian Government Department of Health and Aged Care.
Address: Level 5, 255 Elizabeth Street Sydney NSW 2000
Country: Australia
Postal Address: GPO Box 5480 Sydney NSW 2001
Email: https://www.nps.org.au/
PhRMA is an organisation that strives to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.
Scientific Innovation: biopharmaceutical research and development is key to improving patients’ health and saving lives.
PhRMA’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers and health care providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.
Country
United States of America
Voters for cures is a branch of PhRMA to take action on important policy issues affecting all Americans. It operates within the unique policy and regulatory framework in the United States supports innovation and access to medicines.
Address: 950 F Street, NW Suite 300, Washington, DC 20004
Country: United States of America
The PBS Schedule lists all of the medicines available to be dispensed to patients at a Government-subsidised price. The Schedule is part of the wider Pharmaceutical Benefits Scheme managed by the Department of Health and Aged Care and administered by Services Australia. This schedule is now on-line and updated on a monthly basis. This online searchable version contains:
Country: Australia
Email: pbs@health.gov.au
Pharmacy Research UK (PRUK) is a small independent funder that is the principal funder of pharmacy research in the UK. They are committed to supporting pharmacy to improve the health of the public. To do this, they fund research projects and individual bursaries, helping to develop research skills across the pharmacy sector, to provide an evidence-base to improve the practice of pharmacy, to highlight the vital role of pharmacy in our health services and ultimately to improve public health.
Address: 66-68 East Smithfield, London, E1W 1AW
Country: United Kingdom
Email: 66-68 East Smithfield, London, E1W 1AW
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel first-in-class therapies for orphan and common diseases with high unmet medical needs, leveraging our artificial intelligence (AI)-based PLEOTHERAPY™ platform. Pharnext is an advanced clinical-stage biopharmaceutical company that focuses on:
Disease Molecular Networks: their proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Innovative Drug Combinations: harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Optimal Doses: formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
Pharnext has an advanced clinical-stage pipeline. Two first-in-class products in clinical development
Contact Person / Email
medical@pharnext.com
PLEOTHERAPY™ is Pharnext's proprietary technology platform, systemizes the identification and development of new drug combinations for any disease that currently lack effective treatments. These new treatment candidates – called PLEODRUG™ – are expected to feature high levels of efficacy and safety as they target several disease pathways simultaneously and are formulated with optimal doses of their components.
This new visionary concept in drug development is based on network pharmacology. From all biological data associated with a disease, notably genomic big data, and the use of Artificial Intelligence tools, Pharnext builds the disease molecular network which is a set of interconnected potential therapeutic targets. From this network, Pharnext screens, in silico and experimentally, generic compounds approved for unrelated indications and/or NCEs to develop novel drug combinations that hit multiple highly relevant disease targets. We then create new formulations of the newly identified treatment candidate (each component with a new specific dose and ratio), called PLEODRUG™, that are tested in humans through a full clinical development plan. In addition to a potentially excellent efficacy and safety profile, PLEODRUG™ are expected to offer other potential advantages: fast, affordable development (up to pre-Phase 2 POC in ~2.5 years) and robust intellectual property (Composition of Matters and Method of Use patents).
Pharnext’s PLEOTHERAPY™ approach in drug development is universally applicable to any disease or compound, regardless of development stage or lifecycle status. It has been validated by worldwide-renowned scientists and institutions, including Nobel Prize laureates, but also through R&D collaborations with renowned companies Galapagos and Tasly Pharmaceuticals.
Address: 46 Rue Saint-Lazare 75009 Paris
Country: France
Email: contact@pharnext.com
The PhRMA Foundation fosters biopharmaceutical innovation and value-driven health care by investing in the frontiers of research. The Foundation catalyzes the careers of promising researchers through competitive, peer-reviewed grants and fellowships in the fields of:
The PhRMA Foundation’s Value Assessment Initiative promotes the development of advanced value-assessment so decision makers have better tools to assess high- and low-value care in the U.S. health system. The initiative funds new research and innovative efforts to assess the value of medicines and health care services, improve patient outcomes and reduce inefficiency.
Address: 950 F Street, N.W. Suite 300 Washington, DC 20004
Country: United States of America
Email: info@phrmafoundation.org
The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI. The PMCPA:
Address: Prescription Medicines Code of Practice Authority 2nd Floor Goldings House Hay’s Galleria 2 Hay’s Lane London SE1 2HB
Country: United Kingdom
Psychiatric Drug Effects is a website that has a variety of information about anti-psychotic and antidepressant drugs. It aims to assist service users, carers and health and social care practitioners in achieving a fuller understanding of the impact of medication than is commonly taught in under-graduate and post-graduate university courses.
Email: cclarke@post.com
The Psychotropic Drug Directory provides a source of rapidly accessible information for professional practicing clinicians, advice and references on psychiatric drugs and to act as an aide memory.
Email: binkie@lloyd-reinhold.com
Reconnexion (formerly TRANX) is a not for profit organisation that provides counselling and support for people dependent on tranquillisers (benzodiazepines) and to raise awareness of the risk of dependency associated with long term prescribing of benzodiazepines. The benzodiazepine program actively promotes understanding and awareness of the complications associated with long term use of benzodiazepines to the medical profession, government and in the community. Reconnexion is the only organisation in Australia providing expertise specifically in benzodiazepine use and dependency
Reconnexion collaborated with Federation University to develop an online self-guided benzodiazepine tapering program called BDZ Digital Health. Early evidence shows BDZ Digital Health is just as effective at supporting individuals to safely cease their benzodiazepine or z-drug as face-to-face interventions (like Reconnexion’s benzo counselling program) making it a great alternative for individuals who cannot access our program or who want to do a self-guided taper.
Country
Australia
Recconnexion's experienced counsellors work with you and your GP to design a gradual reduction that suits your needs. Your counsellor will meet regularly with you to work on managing any withdrawal symptoms you may experience, as well as supporting you to overcome issues that emerge as you reduce your benzos such as anxiety, insomnia and depression. Before you begin counselling, you will be stepped through the intake process over the phone. Your first counselling appointment(s) will focus on assessment to ensure you remain very much in control of the process. Most clients then have regular weekly or fortnightly appointments. The length of treatment required varies from person to person – for some people it is relatively quick and straightforward but for others it may take many months.
Country
Australia
A Benzodiazepine Guided Support Group is a facilitated group for people recovering from benzodiazepine withdrawal. Whilst receiving support, you also give help and hope to others through sharing the challenges and the successes you have experienced in withdrawal.
Country
Australia
Reconnexxion's experienced benzodiazepine counsellors can provide free secondary consultations by phone to health professionals working with a patient or client who has issues with benzodiazepine use or withdrawal.
Country
Australia
Address: 1939 Malvern Road Malvern East VIC 3145
Country: Australia
Email: info@reconnexion.org.au
The Royal Pharmaceutical Society is the dedicated professional body for pharmacists in England, Scotland and Wales. They promote pharmacy in the media and government, lead the way in medicines information, and support pharmacists in their education and development
Address: 66 East Smithfield , London
Country: United Kingdom
Email: 66 East Smithfield , London
RxISK is a free, independent drug safety website to help you weigh the benefits of any medication against its potential dangers. RxISK provides free access to information and tools to help you assess the connection between a drug and a side effect.
The Seroxat User Group was set up to provide support and advice to users of seroxat, and to their families and friends. This web site contains information about the aims of the group, as well as research and articles on the effects of Seroxat.
Seroxat is a second generation SSRI (Selective Serotonin Re-Uptake Inhibitor). SSRI’s work by inhibiting serotonin re-uptake transporters thereby increasing serotonin levels in the brain. Serotonin is a chemical which affects the mood. By boosting that chemical the patient should feel better.
Country: United Kingdom
Frank is a website that provides honest information about drugs.
Email: frank@talktofrank.com
The Commission on Human Medicines (CHM) advises ministers on the safety, efficacy and quality of medicinal products. They’re responsible for:
Country: United Kingdom
Email: info@mhra.gov.uk
Therapeutic Goods Administration (TGA) are Australia's government authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods. We regulate medicines, medical devices and biologicals to help Australians stay healthy and safe.
Country: Australia
Postal Address: info@tga.gov.au
Email: info@tga.gov.au
